Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Seyitler Kimyanayi ASIST:SEYKM -2.47%62 EV-to-EBIT is 16.03 as of Sep. 03, 2026, which is 6% above its 10-year median of 15.14. GuruFocus rates IST:SEYKM with a GF Score™ of 62/100 and a GF Value™ of ₺2.70 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 474 Medical Devices & Instruments companies, Seyitler Kimyanayi AS ranks better than 56.12% on this metric.
The historical rank and industry rank for Seyitler Kimyanayi AS's EV-to-EBIT or its related term are showing as below:
IST:SEYKM'
s EV-to-EBIT Range Over the Past 10 Years
Min: -40.64 Med: 15.14 Max: 134.8
Current: 16.02
During the past 12 years, the highest EV-to-EBIT of Seyitler Kimyanayi AS was 134.80. The lowest was -40.64. And the median was 15.14.
IST:SEYKM's EV-to-EBIT is ranked better than 56.12% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 18.7
vs IST:SEYKM: 16.02
Seyitler Kimyanayi AS (IST:SEYKM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Seyitler Kimyanayi AS's Enterprise Value for the quarter that ended in Mar. 2026 was ₺614.0 Mil.
Seyitler Kimyanayi AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺37.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IST:SEYKM vs ISRG, BDX, RMD: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Seyitler Kimyanayi AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seyitler Kimyanayi AS EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seyitler Kimyanayi AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Seyitler Kimyanayi AS's EV-to-EBIT falls into.
Seyitler Kimyanayi AS's current Enterprise Value is ₺598.0 Mil.
Seyitler Kimyanayi AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺37.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seyitler Kimyanayi AS (IST:SEYKM) has a EV-to-EBIT of 16.03 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Seyitler Kimyanayi AS and its competitors. This is near median its historical median of 15.14. According to the industry distribution chart, Seyitler Kimyanayi AS ranks #208 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 43.9%.
Is Seyitler Kimyanayi AS's EV-to-EBIT too high?
Seyitler Kimyanayi AS's current EV-to-EBIT of 16.03 is near median its 10-year median of 15.14. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Seyitler Kimyanayi AS's value of 16.03 is 14.3% below this industry median. Based on the distribution chart, Seyitler Kimyanayi AS ranks #208 out of 474 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Seyitler Kimyanayi AS has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Seyitler Kimyanayi AS's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Seyitler Kimyanayi AS ranks #208 out of 474 companies for EV-to-EBIT. This puts Seyitler Kimyanayi AS in the upper half of its industry. The industry median EV-to-EBIT is 18.70. Seyitler Kimyanayi AS's value of 16.03 is 14.3% below this benchmark. While the company's 10-year median is 15.14 vs. the industry median of 18.70, Seyitler Kimyanayi AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seyitler Kimyanayi AS's current EV-to-EBIT of 16.03 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Seyitler Kimyanayi AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seyitler Kimyanayi AS's current EV-to-EBIT is 16.03, which is near median its own 10-year median of 15.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seyitler Kimyanayi AS stock overvalued right now?
Based on GuruFocus' analysis, Seyitler Kimyanayi AS (IST:SEYKM) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺2.70, compared to a current price of ₺4.34 — trading 60.7% above its estimated fair value. The current EV-to-EBIT is 16.03, which is near median its 10-year median of 15.14 and 14.3% below the Medical Devices & Instruments industry median of 18.70. Seyitler Kimyanayi AS's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Seyitler Kimyanayi AS (IST:SEYKM), the current EV-to-EBIT is 16.03 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seyitler Kimyanayi AS (IST:SEYKM) Overvalued in 2026?
Based on GuruFocus' analysis, Seyitler Kimyanayi AS stock appears to be overvalued.
The current stock price of ₺4.34 is trading 60.7% above its estimated GF Value™ of ₺2.70.
GuruFocus considers Seyitler Kimyanayi AS to be Significantly Overvalued.
Key valuation signals for IST:SEYKM:
EV-to-EBIT: 16.03 (near median its 10-year median of 15.14)
GF Value™: ₺2.70 vs. price of ₺4.34 (60.7% above fair value)
Industry Position: 14.3% below the Medical Devices & Instruments median (#208 of 474)
No single metric tells the full story. See the IST:SEYKM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seyitler Kimya Sanayi AS is engaged in manufacturing Medical plaster, first aid plaster, and capsicum perforated rheumatism plaster. Its products include Medical Tapes, Medical fluids, Wound Dressing, First-Aid plaster and Eye products among others.
62GF Score
Get the complete analysis for IST:SEYKM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:SEYKM has been successfully added to your 
